■自2019年以来,Perampanel(PER)在中国被认可为局灶性癫痫发作的辅助治疗方法,有和没有意识受损,以及从局灶性强直阵挛性癫痫发作到双侧强直阵挛性癫痫发作的过渡。在中国,关于PER治疗卒中后癫痫(PSE)的疗效的研究有限。实证研究对于指导治疗方案至关重要。我们进行了一项回顾性研究,以评估2019年10月至2023年7月期间治疗的58例PSE患者中PER的疗效和耐受性。
■这项研究包括58名PSE患者,作为单一疗法或作为辅助疗法的一部分,用PER治疗,并接受了至少6个月的随访。这项研究评估了癫痫发作频率的变化,不良事件(AE),药物保留率,维持剂量,以及PER治疗后的不良反应。
■该研究包括58名PSE患者,男性占60.3%,女性占39.7%,年龄从18岁到89岁不等,大多在61-70岁年龄段。缺血性卒中占58.6%,出血性卒中占41.4%。局灶性癫痫发作,有或没有意识受损,在62.1%的患者中发现,32.8%的患者从局灶性强直阵挛性发作过渡到双侧强直阵挛性发作。3个月和6个月的PER保留率分别为94.8%和84.5%,最常用的维持剂量为4mg/天(41.28%)。在辅助治疗组中,3个月有效率为66.7%,6个月有效率为78.6%,与单药治疗组相比,3个月时为80.0%,6个月时为85.7%。在功效分析中,标准为癫痫发作频率降低≥50%,3个月和6个月的总有效率分别为69.1%和79.6%,分别。46.6%的患者出现不良反应,主要涉及烦躁和嗜睡(均为27.6%),辅助治疗组和单药治疗组之间的发生率没有显着差异(P>0.05)。
■PER在中国PSE患者中表现出良好的疗效和耐受性,可能在较低的剂量。
UNASSIGNED: Since 2019, Perampanel (PER) has been endorsed in China as an adjunctive treatment for focal seizures, both with and without impaired awareness, and for the transition from focal to bilateral tonic-clonic seizures. Limited research exists regarding the efficacy of PER in treating post-stroke epilepsy (PSE) in China. Empirical studies are essential to guide treatment protocols. We conducted a retrospective study to assess the efficacy and tolerability of PER in 58 PSE patients treated between October 2019 and July 2023.
UNASSIGNED: This study encompassed 58 patients with PSE, treated with PER either as monotherapy or as part of adjunctive therapy, and underwent follow-up for a minimum duration of 6 months. The study assessed changes in seizure frequency, adverse events (AEs), drug retention rate, maintenance dose, and adverse reactions following PER treatment.
UNASSIGNED: The study included 58 PSE patients, with 60.3% males and 39.7% females, ranging in age from 18 to 89, mostly within the 61-70 age group. Ischemic strokes constituted 58.6% of cases, while hemorrhagic strokes accounted for 41.4%. Focal seizures, either with or without impaired awareness, were noted in 62.1% of patients, and a transition from focal to bilateral tonic-clonic seizures was seen in 32.8%. The retention rates for PER at 3 and 6 months stood at 94.8% and 84.5% respectively, and the most commonly administered maintenance dose was 4 mg/day (41.28%). In the adjunctive therapy group, efficacy rates were 66.7% at 3 months and 78.6% at 6 months, compared to 80.0% at 3 months and 85.7% at 6 months in the monotherapy group. In the efficacy analysis, with a criterion of ≥50% reduction in seizure frequency, the overall efficacy rates at 3 and 6 months were 69.1% and 79.6%, respectively. Adverse reactions occurred in 46.6% of patients, primarily involving irritability and somnolence (both 27.6%), with no marked difference in incidence between the adjunctive and monotherapy groups (P > 0.05).
UNASSIGNED: PER exhibits favorable efficacy and tolerability in Chinese PSE patients, possibly at lower doses.